Thromboxane A2 receptor antagonists, such as ifetroban, inhibit solid tumor metastasis. The formation of surface and microscopic lung metastases are inhibited. Thromboxane A2 receptor antagonists can inhibit the tumor metastasis process without affecting the growth or development of a primary tumor.

Thromboxane A2 receptor antagonists, such as ifetroban, inhibit solid tumor metastasis. The formation of surface and microscopic lung metastases are inhibited. Thromboxane A2 receptor antagonists can inhibit the tumor metastasis process without affecting the growth or development of a primary tumor.

To provide a transdermal drug delivery patch that can be suitably used for an immediate release application of a pharmaceutical with a comparatively low molecular weight. A transdermal drug delivery patch, provided with a matrix and at least one drug disposed within the matrix, wherein the matrix has a water holding capacity of 10 mg/cm.sup.2 or less, and the drug is a pharmaceutical having a molecular weight of 5000 or less.

To provide a transdermal drug delivery patch that can be suitably used for an immediate release application of a pharmaceutical with a comparatively low molecular weight. A transdermal drug delivery patch, provided with a matrix and at least one drug disposed within the matrix, wherein the matrix has a water holding capacity of 10 mg/cm.sup.2 or less, and the drug is a pharmaceutical having a molecular weight of 5000 or less.

The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.

The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.

The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

Disclosed are antimicrobial compositions and formulations directed against a broad range of bacteria and Pseudomonas aeruginosa biofilms. In an aspect, the compositions and formulations do not engender resistance. In an aspect, in combination with antibiotics, the compositions and formulations slow the development of antibiotic-resistance and greatly improve bacterial susceptibility to multiple classes of antibiotics.